Crohn Disease Clinical Trial
Official title:
The Feasibility of Following the Crohn's Diet
Verified date | February 2019 |
Source | King's College London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A research team from King's College London are investigating how diet can be used as a
treatment for Crohn's disease. The investigators have designed a new diet and eventually wish
to test whether the diet can be used to manage Crohn's disease and reduce gut inflammation.
Before doing this, the investigators need to find out how practical it is for people to
follow the diet for 14 days by conducting this 'feasibility' study. A feasibility study is a
small study that aims to highlight any issues before informing the design of a larger
research trial.
The diet the investigators have designed is called the Crohn's Diet. The evidence for this
diet is based on recent research which suggests that certain food ingredients may be involved
in triggering gut inflammation.
The study's primary aim is to assess the practicalities of following the Crohn's Diet. It
will also assess compliance to the Crohn's Diet and if following it changes the nutritional
balance from the normal diet.
Status | Completed |
Enrollment | 20 |
Est. completion date | December 18, 2018 |
Est. primary completion date | December 18, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria will include: 1. Adults aged =18 years with a diagnosis of Crohn's disease 2. Stable Crohn's disease (as defined as self-reported: no change in Crohn's disease medication in the last 3 months; no Crohn's disease surgery in the last 6 months; no hospital admissions related to Crohn's disease in the last 6 months; no new perianal Crohn's disease in the last 6 months). 3. Individuals with a Body Mass Index (BMI) of = 18.5 kg/m2 4. Individuals able to give informed consent 5. Individuals able to understand and read English 6. Individuals willing to provide consent in this study which involves a dietary change for 14 days Exclusion Criteria will include: 1. Unexplained/unintentional weight loss in the past 6 months 2. Major co-morbidities; for example, diabetes, coeliac disease, major active psychiatric conditions or current eating disorders. 3. Current Crohn's disease therapy with any of the following: corticosteroids, exclusive or partial enteral nutrition (liquid nutrition), and any participants prescribed oral nutrition supplements for nutrition support. 4. Individuals who report to be pregnant or lactating 5. Individuals with specific, complex dietary needs (based on the dietitian's judgment), such as multiple food allergies, in which the additional burden of the Crohn's Diet would pose a nutrition risk. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | King's College London | London |
Lead Sponsor | Collaborator |
---|---|
King's College London |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of following the Crohn's Diet: questionnaire | Method: Collation of participant feedback during the Crohn's Diet and administer diet feasibility questionnaire. This questionnaire uses an adapted Education Method Usability Scale (Bangor et al. 2008) ('strongly agree' to 'strongly disagree' style scale) and open questions. | Throughout the 14-day intervention | |
Secondary | Acceptability of following the Crohn's Diet: questionnaire | Method: Administer questionnaires on diet acceptability, including the Food-Related Quality of Life in Inflammatory Bowel Disease questionnaire (Hughes et al 2016). | Throughout the 14-day intervention and within one week of completing the intervention | |
Secondary | Participant compliance to the Crohn's Diet | Method: Dietitian monitoring of compliance during the trial. A 7-day food diary will quantify compliance alongside a questionnaire which explores reasons for potential non-compliance. | Throughout the 14-day intervention | |
Secondary | Impact of the Crohn's Diet on habitual dietary intake | Method: 7-day food diaries to compare nutrient intake and explore changes in dietary patterns. | One week before the intervention and throughout the 14-day intervention | |
Secondary | Impact of the Crohn's Diet on BMI | Method: Participants will undergo anthropometric assessment, including weight and height to report BMI. | One week before the intervention and within one week of completing the 14-day intervention | |
Secondary | Impact of the Crohn's Diet on gastrointestinal symptoms | Method: Administer the PRO-2 questionnaire (Khanna et al 2015). | One week before the intervention and within one week of completing the 14-day intervention | |
Secondary | Impact of the Crohn's Diet on perceived disease control | Method: Administer questionnaires, including the Inflammatory Bowel Disease Control-8 questionnaire (IBD-C-8) (Bodger et al. 2013). | One week before the intervention and within one week of completing the 14-day intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04046913 -
The ADDapt Diet in Reducing Crohn's Disease Inflammation
|
N/A | |
Recruiting |
NCT05169593 -
Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy
|
Phase 4 | |
Recruiting |
NCT06116604 -
Early Bowel Resection for Terminal Ileal Crohn's Disease
|
||
Recruiting |
NCT05294107 -
Intestinal Organoids
|
N/A | |
Recruiting |
NCT05627128 -
A Culturally Tailored Dietary Intervention to Treat Crohn's Disease
|
N/A | |
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Withdrawn |
NCT04349449 -
ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice
|
||
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Completed |
NCT03058679 -
Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease
|
N/A | |
Completed |
NCT02871635 -
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity
|
Phase 3 | |
Recruiting |
NCT04539665 -
Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease.
|
N/A | |
Recruiting |
NCT04266600 -
Extended Mesenteric Excision in Ileocolic Resections for Crohn's Disease
|
N/A | |
Recruiting |
NCT03913572 -
Treatment of Perianal Disease Using Adipose-derived Stem Cells
|
||
Completed |
NCT03606499 -
Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
|
||
Completed |
NCT03668249 -
A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
|
||
Terminated |
NCT04102111 -
A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease
|
Phase 2 | |
Recruiting |
NCT04997733 -
Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal
|
Phase 3 | |
Recruiting |
NCT05906576 -
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
|
Phase 4 | |
Not yet recruiting |
NCT04398836 -
Preoperative Nutrition for Crohn's Disease Patients
|
Phase 3 | |
Not yet recruiting |
NCT04502303 -
18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease
|
Phase 2 |